Of course. Here are the complete tables with the requested modifications made to the "Immunosuppressive treatment, n (%)" section in Table B.

# Table A. Treatment Approach

| row                        | subrow                      | Total      | Monotherapy   | Combination   | p-value   |
|:---------------------------|:----------------------------|:-----------|:--------------|:--------------|:----------|
| N =                        |                             | 104        | 33            | 57            |           |
| First-line therapy¹, n (%) |                             |            |               |               |           |
|                            | Remdesivir                  | 36 (34.6%) | 13 (39.4%)    | 21 (36.8%)    | 0.988     |
|                            | Molnupiravir                | 14 (13.5%) | 5 (15.2%)     | 9 (15.8%)     | 1.000     |
|                            | Standard 5-day Paxlovid     | 31 (29.8%) | 5 (15.2%)     | 25 (43.9%)    | 0.011     |
|                            | Other antivirals            | 13 (12.5%) | 5 (15.2%)     | 4 (7.0%)      | 0.279     |
|                            | None                        | 6 (5.8%)   | 2 (6.1%)      | 2 (3.5%)      | 0.622     |
| Last line therapy², n (%)  |                             |            |               |               | <0.001    |
|                            | Combination therapy         | 63 (60.6%) | 0 (0.0%)      | 57 (100.0%)   |           |
|                            | Monotherapy                 | 41 (39.4%) | 33 (100.0%)   | 0 (0.0%)      |           |
| Treatment courses, n (%)   |                             |            |               |               | 1.000     |
|                            | Single prolonged course     | 99 (95.2%) | 31 (93.9%)    | 54 (94.7%)    |           |
|                            | Multiple courses            | 5 (4.8%)   | 2 (6.1%)      | 3 (5.3%)      |           |
| Duration                   |                             |            |               |               | 0.206     |
|                            | Median duration, days (IQR) | 10 (10-15) | 10 (10-15)    | 10 (10-14)    |           |
|                            | Duration range, days        | 5-61       | 7-36          | 5-61          |           |

- NMV-r, nirmatrelvir-ritonavir.    
1: Any treatment administered prior to extended nirmatrelvir-ritonavir, including standard 5-day Paxlovid courses with or without other antivirals.    
2: Extended nirmatrelvir-ritonavir regimens (with or without concurrent antivirals) when no subsequent antiviral therapy was administered.  

\newpage
# Table B. Demographics and Clinical Characteristics

| row                                | subrow                   | Total      | Monotherapy   | Combination   | p-value   |
|:-----------------------------------|:-------------------------|:-----------|:--------------|:--------------|:----------|
| N =                                |                          | 104        | 33            | 57            |           |
| Age, median (IQR)                  |                          | 66 (58-73) | 63 (55-71)    | 67 (59-76)    | 0.061     |
| Female sex, n (%)                  |                          | 35 (34.7%) | 11 (34.4%)    | 21 (38.2%)    | 0.901     |
| Underlying conditions, n (%)       |                          |            |               |               |           |
|                                    | Hematological malignancy | 93 (89.4%) | 28 (84.8%)    | 53 (93.0%)    | 0.279     |
|                                    | Autoimmune               | 11 (10.6%) | 4 (12.1%)     | 4 (7.0%)      | 0.458     |
|                                    | Transplantation          | 4 (3.8%)   | 3 (9.1%)      | 1 (1.8%)      | 0.138     |
| Immunosuppressive treatment, n (%) |                          |            |               |               |           |
|                                    | Anti-CD20                | 79 (76.0%) | 24 (72.7%)    | 47 (82.5%)    | 0.411     |
|                                    | CAR-T                    | 4 (3.8%)   | 0 (0.0%)      | 4 (7.0%)      | 0.292     |
|                                    | HSCT                     | 4 (3.8%)   | 3 (9.1%)      | 1 (1.8%)      | 0.138     |
|                                    | Other                    | 13 (12.5%) | 5 (15.2%)     | 4 (7.0%)      | 0.279     |
|                                    | None                     | 6 (5.8%)   | 2 (6.1%)      | 2 (3.5%)      | 0.622     |
|                                    | Mixed                    | 2 (1.9%)   | 1 (3.0%)      | 1 (1.8%)      | 1.000     |
| Glucocorticoid use, n (%)          |                          | 47 (45.2%) | 13 (39.4%)    | 29 (50.9%)    | 0.405     |
| SARS-CoV-2 vaccination, n (%)      |                          | 95 (91.3%) | 30 (90.9%)    | 53 (93.0%)    | 0.704     |
| Mean Vaccination doses, n (range)  |                          | 3.3 (2-8)  | 3.3 (2-6)     | 3.3 (2-8)     | 0.651     |
| Thoracic CT changes, n (%)         |                          | 62 (59.6%) | 17 (51.5%)    | 38 (66.7%)    | 0.231     |
| Treatment setting¹, n (%)          |                          |            |               |               | 0.714     |
|                                    | Hospital                 | 55 (52.9%) | 17 (51.5%)    | 33 (57.9%)    |           |
|                                    | Outpatient               | 49 (47.1%) | 16 (48.5%)    | 24 (42.1%)    |           |

- NMV-r, nirmatrelvir-ritonavir.    
1: Treatment setting where prolonged NMV-r was administered.    

\newpage
# Table C. Detailed Patient Characteristics

| row                                                     | subrow           | Total       | Monotherapy   | Combination   | p-value   |
|:--------------------------------------------------------|:-----------------|:------------|:--------------|:--------------|:----------|
| Haematological malignancy, n (%)                        |                  |             |               |               |           |
|                                                         | FL               | 30 (28.8%)  | 9 (27.3%)     | 18 (31.6%)    | 0.849     |
|                                                         | Other¹           | 18 (17.3%)  | 7 (21.2%)     | 8 (14.0%)     | 0.557     |
|                                                         | NHL              | 7 (6.7%)    | 3 (9.1%)      | 3 (5.3%)      | 0.665     |
| Autoimmune disease, n (%)                               |                  |             |               |               |           |
|                                                         | Other²           | 7 (6.7%)    | 2 (6.1%)      | 3 (5.3%)      | 1.000     |
|                                                         | RA               | 2 (1.9%)    | 2 (6.1%)      | 0 (0.0%)      | 0.132     |
| Transplantation, n (%)                                  |                  |             |               |               |           |
|                                                         | LT               | 2 (1.9%)    | 2 (6.1%)      | 0 (0.0%)      | 0.132     |
|                                                         | KT               | 2 (1.9%)    | 1 (3.0%)      | 1 (1.8%)      | 1.000     |
| Duration of SARS-CoV-2 replication (days), median (IQR) |                  | 64 (33-120) | 79 (33-135)   | 71 (38-116)   | 0.766     |
| SARS-CoV-2 genotype, n (%)                              |                  |             |               |               |           |
|                                                         | Other            | 56 (53.8%)  | 18 (54.5%)    | 28 (49.1%)    | 0.782     |
|                                                         | BA.5             | 31 (29.8%)  | 6 (18.2%)     | 21 (36.8%)    | 0.105     |
|                                                         | BA.1             | 9 (8.7%)    | 5 (15.2%)     | 4 (7.0%)      | 0.279     |
|                                                         | BA.2             | 8 (7.7%)    | 4 (12.1%)     | 4 (7.0%)      | 0.458     |
| Prolonged viral shedding (≥ 14 days), n (%)             |                  | 90 (86.5%)  | 33 (100.0%)   | 57 (100.0%)   | 1.000     |
| Survival, n (%)                                         |                  | 94 (90.4%)  | 31 (93.9%)    | 53 (93.0%)    | 1.000     |
| Adverse events, n (%)                                   |                  |             |               |               |           |
|                                                         | None             | 98 (94.2%)  | 32 (97.0%)    | 52 (91.2%)    | 0.409     |
|                                                         | Other            | 5 (4.8%)    | 1 (3.0%)      | 4 (7.0%)      | 0.648     |
|                                                         | Thrombocytopenia | 1 (1.0%)    | 0 (0.0%)      | 1 (1.8%)      | 1.000     |

1: Other includes MCL, LPL, MALT lymphoma and similar entities.    
2: Other includes ANCA-Vasculitis, CREST, MCD, MCTD, NMDA-encephalitis, SSc, LT, KT, CU.  

   
# Table D. Outcomes in all cohorts

| row                                  | Total      | Monotherapy   | Combination   |   p-value |
|:-------------------------------------|:-----------|:--------------|:--------------|----------:|
| SARS-CoV-2 Persistence¹, n (%)       | 11 (10.6%) | 3 (9.1%)      | 5 (8.8%)      |     1     |
| All-cause mortality², n (%)          | 10 (9.6%)  | 2 (6.1%)      | 4 (7.0%)      |     1     |
| SARS-CoV-2-related mortality³, n (%) | 5 (4.8%)   | 1 (3.0%)      | 2 (3.5%)      |     1     |
| AE⁴, n (%)                           | 6 (5.8%)   | 1 (3.0%)      | 5 (8.8%)      |     0.409 |

1: defined as subjects with parameter “eradication outcome successful: no”    
2: defined as subjects with parameter “survival outcome: no”    
3: defined as subjects with parameters “eradication outcome successful: no” AND “survival outcome: no”    
4: defined as subjects with parameter “adverse events: yes”  
